动物实验,2型糖尿病 z-bo 2020-08-20 590

　　Objective: To explore the effectiveness and feasibility of vaccination intervention with human-derived RBP-4 as the target of insulin resistance, and to provide basic research data for the development of new treatments for type 2 diabetes.

　　Method: T7 phage was used as a carrier for expressing human RBP-4 vaccine and subcutaneously immunizing mice with type 2 diabetes. At the same time, set an empty vector group and an empty control group. After two immunizations, the humoral immunity level was measured at different times. Animals were sacrificed at 20 weeks for fasting blood sugar and body weight and pathological examinations were performed.

　　Result: The RBP-4 vaccine effectively induced the production of anti-RBP-4 IgG antibodies, which peaked at 12 weeks. At the same time, starting from the 8th week, the fasting blood glucose level of the immunized group gradually decreased, and at the 12th week, the carrier was empty. There is a significant difference between the control group and the blank group, which has always remained below the incidence of type 2 diabetes (7 mmol/L). During the experiment, the type 2 diabetic mice showed no obvious abnormalities in the immunized and empty carrier groups, such as curly, upright hair, nose scratching, convulsions, and the mice's heart, liver, spleen, lungs and kidneys. No obvious pathological changes were observed in the tissues, and the RBP-4 vaccine was shown to be safe.

　　Conclusion: RBP-4 vaccine can significantly reduce blood glucose levels in type 2 diabetic mice, which may be a new breakthrough in the treatment of insulin resistance.